)
)
)
Oncolytics
Company Description: Oncolytics is developing pelareorep, the only dsRNA REO virus being developed as an immunotherapy treatment for various tumors, including KRAS mutant MSS mCRC and 2L anal cancer. Pelareorep has achieved 2-3x the efficacy benchmarks versus standard of care treatment in colorectal, anal and pancreatic cancer. The company is led by former head of legal and strategy at Ambrx, Jared Kelly.
Goal for Presentation: The presentation will summarize clinical data and layout the company’s 2026 development plan where it will have preliminary data in 2L KRAS mutant MSS CRC and 2L and later SCAC, with the latter being a single arm registration study.
Additional Comments:
Who referred you to this application?: Centerview Partners
Goal for Presentation: The presentation will summarize clinical data and layout the company’s 2026 development plan where it will have preliminary data in 2L KRAS mutant MSS CRC and 2L and later SCAC, with the latter being a single arm registration study.
Additional Comments:
Who referred you to this application?: Centerview Partners
What is your next catalyst (value inflection) update?
FDA Type C meeting to align on single arm registration study in anal cancer indication where there is currently no approved FDA treatment.
Year Founded
1999
Lead Product in Development
Pelareorep
Development Phase of Lead Product
Phase III
Exchange
Nasdaq
Ticker
ONCY
CEO/Top Company Official
Jared Kelly
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
